Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26041859 | 0.99 | CTSK (0.48) | CTSKBTKHSD11B1CYP2C9KCNA3 | |
| SCHEMBL25368817 | 0.87 | CTSK (0.47) | CTSKBTKHSD11B1CYP2C9KCNA3 | |
| SCHEMBL29440881 | 0.86 | CTSK (0.46) | CTSKBTKHSD11B1CYP2C9KCNA3 | |
| SCHEMBL26650258 | 0.76 | CTSK (0.43) | CTSKBTKHSD11B1CYP2C9CA1 | |
| SCHEMBL854270 | 0.74 | HSD11B1 (0.41) | CTSKBTKHSD11B1CYP2C9CA1 | |
| SCHEMBL359203 | 0.74 | CTSK (0.59) | CTSKBTKHSD11B1CYP2C9KCNA3 | |
| SCHEMBL18901529 | 0.73 | BTK (0.49) | CTSKBTKHSD11B1CYP2C9KCNA3 | |
| SCHEMBL14100893 | 0.73 | BTK (0.49) | CTSKBTKHSD11B1CYP2C9KCNA3 | |
| Acetic Acid SCHEMBL8483326 | 0.73 | CTSK (0.55) | CTSKBTKHSD11B1CYP2C9KCNA3 | |
| SCHEMBL19547113 | 0.72 | BTK (0.50) | CTSKBTKHSD11B1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357271-A1 | MACROCYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-11-09 | — | — | US | disclosed |
| EP-4223368-A1 | MACROCYCLE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2023-08-09 | — | — | EP | disclosed |
| CN-116348472-A | Macrocyclic compounds | 旭化成制药株式会社 | 2023-06-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357271-A1 | MACROCYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | CTSK 2804/4885BTK 108/4885HSD11B1 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.